Sensus Healthcare's Q2 Revenue Collapses 68% as Key Customer Orders Vanish

What happened

Sensus Healthcare reported Q2 2026 revenue of $2.3 million, a $5.0 million decline from the prior-year quarter, representing a roughly 68% year-over-year collapse. The drop was attributed to fewer system sales, underscoring the continued concentration risk from a dominant U.S. dermatology customer that has sharply reduced orders. This result directly contradicts the bullish thesis predicated on new SRT-specific CPT codes effective January 2026 driving increased adoption and system placements. The company's Fair Deal program and international expansion, previously highlighted as diversification levers, failed to compensate for the loss of large-customer volume. With revenue at this level, Sensus is now operating far below the scale needed to support its cost structure, and the balance sheet, while still holding cash, faces increasing pressure as losses mount.

Implication

The thesis that reimbursement changes would spur a rapid recovery is now invalidated. Investors should reassess the bear case, which implied a value near $3 per share, but even that may be optimistic if revenue continues to decline. The company's dependence on a single customer and failure to diversify make it a highly speculative position with limited downside protection. Waiting for evidence of stabilization is prudent, and new capital should likely avoid the stock until there are clear signs of order recovery or a successful strategic pivot.

Thesis delta

The previous WAIT rating was based on expectations that CPT codes would drive demand and that diversification would reduce concentration risk. The Q2 2026 results show that these catalysts have not materialized, and revenue has fallen dramatically, breaking the core investment thesis. The thesis now shifts from cautious optimism to structural decline with significant downside risk.